RxDoctor Payments Data

Joseph Bobrowski, MD

Internal Medicine · Covington, LANPI 1609870013

Payments from drug & device makers

$403in general payments, 2019–2025

Across 17 payments — averaging $23.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$140
  • Johnson & Johnson$46
  • Abbott$25
  • AbbVie$24
  • Hikma Pharmaceuticals USA$23
  • Siemens Medical Solutions USA, Inc.$20
  • plus $125 from 8 others

What the payments were for

  • Food & beverage$403100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$403 in reported general payments places this provider in the 50th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$95,943
Medicare patients
464
Services billed
1,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide111$152,541
OzempicSemaglutide85$131,117
JanuviaSitagliptin Phosphate91$107,015
TrulicityDulaglutide69$102,242
EliquisApixaban94$100,025
XareltoRivaroxaban28$33,759
MyrbetriqMirabegron19$25,163
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$23,859
Breo ElliptaFluticasone/Vilanterol26$19,780
FarxigaDapagliflozin Propanediol18$15,584
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$13,870
LinzessLinaclotide15$13,527
Soliqua 100-33Insulin Glargine/Lixisenatide14$12,388
VascepaIcosapent Ethyl29$11,933
JardianceEmpagliflozin12$9,843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$140$133,59297 claims
PfizerEliquis$14$100,02594 claims
GSKTrelegy Ellipta, Breo Ellipta$18$43,63958 claims
Johnson & JohnsonXarelto$46$33,75928 claims
Astellas Pharma US IncMyrbetriq$14$25,16319 claims
AbbVieLinzess, Synthroid$24$20,521108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →